Radiopharm Theranostics Limited (RADX)

AU — Healthcare Sector
Peers: CELZ  BCDA  APVO  APRE  KPRX  QNRX  EPIX  HCWB  MTNB  TTNP 

Automate Your Wheel Strategy on RADX

With Tiblio's Option Bot, you can configure your own wheel strategy including RADX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol RADX
  • Rev/Share 0.0
  • Book/Share 0.0
  • PB 0.0
  • Debt/Equity 0.0
  • CurrentRatio 3.374
  • ROIC 0.0

 

  • MktCap 10690561.8234
  • FreeCF/Share 0.0
  • PFCF -0.3654
  • PE 0.0
  • Debt/Assets 0.0
  • DivYield 0
  • ROE 0.0

 

  • Rating D+
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation RADX B. Riley Securities -- Buy -- $15 March 12, 2025

News

About Radiopharm Theranostics Limited (RADX)

  • IPO Date 2024-12-05
  • Website https://www.radiopharmtheranostics.com
  • Industry Biotechnology
  • CEO Riccardo Canevari
  • Employees None
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors. It has strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.